Divya Delhi: Sun Pharmaceutical Industries Ltd has announced its biggest-ever overseas acquisition, agreeing to buy US-based Organon & Co for $11.8 billion (approximately ₹98,000 crore) in an all-cash deal. The transaction marks one of the largest cross-border acquisitions by an Indian company.Under the agreement, Sun Pharma will pay $14 per share, representing a premium of over 24% to Organon’s closing price on April 24. Following the announcement, Sun Pharma’s shares rose nearly 7% to close at ₹1,734 on the BSE.The acquisition significantly expands Sun Pharma’s global footprint, adding access to more than 140 markets, including China, and strengthening its presence in key therapeutic areas such as women’s health, biosimilars, and established medicines. Organon brings a portfolio of over 70 products and six manufacturing facilities worldwide.Once completed, the combined entity is expected to double Sun Pharma’s revenue to $12.4 billion and EBITDA to $3.7 billion, placing it among the top 25 global pharmaceutical companiesOrganon, which was spun off from Merck & Co. in 2021, enhances Sun Pharma’s capabilities in fast-growing segments. Chairman Dilip Shanghvi said the deal provides immediate scale in biosimilars, a space that would otherwise take years to build organically Analysts view the deal as financially disciplined, backed by strong cash flows and strategic alignment with Sun Pharma’s growth ambitions.
